Replies to post #223114 on Biotech Values

[DewDiligence]

ABUS is a turnaround opportunity insofar as the investment community has written them off as a failure in HBV (e.g. #msg-144116381), but this program may be in better shape than investors think.

I don’t own the stock, but I picked it in the SI charity contest.